These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 25687850)

  • 1. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
    Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.
    Lee SJ; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2015 Nov; 90(2):261-6. PubMed ID: 26371700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
    Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
    Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between different EGFR mutation status and survival in pemetrexed-based chemotherapy for advanced non-small cell lung cancer].
    Jia B; He XH; Yang S; Wang ZP; Li JL; Wang Y; Wang HY; Xing PY; Liu YT; Shi YK
    Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(46):3659-62. PubMed ID: 24534344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
    Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.
    Xu J; Zhang X; Yang H; Ding G; Jin B; Lou Y; Zhang Y; Wang H; Han B
    Oncotarget; 2016 Oct; 7(42):68442-68448. PubMed ID: 27637087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
    Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.